Keyword: Ono Pharmaceutical
The deal gives Ono the chance to license antibodies and small molecules advanced by Cancer Research UK and LifeArc.
Bristol-Myers Squibb has licensed a phase 1 immuno-oncology drug from Japan’s Ono in a $40 million upfront pact.
Array claims $31.6 million upfront from Ono for rights to binimetinib and encorafenib in Japan and South Korea, adding to its deal with Pierre Fabre in Europe.
Japanese drugmaker Seikagaku has taken a step towards lining up a big pharma partner for its phase 3 osteoarthritis drug SI-613.
In our EuroBiotech roundup this week, Biopharma Credit completes $762 million IPO, BerGenBio prices NOK 400 million IPO, Merck inks Avillion deal and more.